Katherine A Hoadley
Overview
Explore the profile of Katherine A Hoadley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
24809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Felsheim B, Fernandez-Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):24.
PMID: 40057511
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that remains challenging to target with traditional therapies and to predict risk. We provide a comprehensive characterization of 238 stage...
2.
Van Alsten S, Love M, Calhoun B, Butler E, Perou C, Hoadley K, et al.
Cancer Res
. 2025 Jan;
PMID: 39879109
Cancer genomics consortia have identified somatic drivers of breast cancer subtypes. However, these studies have predominantly included older, non-Black women, and the related socioeconomic status (SES) data is limited. Increased...
3.
Ellrott K, Wong C, Yau C, Castro M, Lee J, Karlberg B, et al.
Cancer Cell
. 2025 Jan;
43(2):195-212.e11.
PMID: 39753139
Molecular subtypes, such as defined by The Cancer Genome Atlas (TCGA), delineate a cancer's underlying biology, bringing hope to inform a patient's prognosis and treatment plan. However, most approaches used...
4.
Fernandez-Martinez A, Fernandez-Martinez A, Tanioka M, Tanioka M, Ahn S, Ahn S, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706338
Background: In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology...
5.
Lee D, Li Y, Olsson L, Hamilton A, Calhoun B, Hoadley K, et al.
Breast Cancer Res
. 2024 Dec;
26(1):177.
PMID: 39633505
Background: Breast cancer subtypes Luminal A and Luminal B are classified by the expression of PAM50 genes and may benefit from different treatment strategies. Machine learning models based on H&E...
6.
Debeljak M, Cho S, Downs B, Considine M, Avin-McKelvey B, Wang Y, et al.
Breast Cancer Res
. 2024 Dec;
26(1):178.
PMID: 39633428
Background: Ductal carcinoma in-situ (DCIS) is a pre-invasive form of invasive breast cancer (IBC). Due to improved breast cancer screening, it now accounts for ~ 25% of all breast cancers....
7.
Sturgill I, Raab J, Hoadley K
NAR Cancer
. 2024 Nov;
6(4):zcae045.
PMID: 39554490
Aberrant expression of the ( associated protein 1) tumor suppressor gene is a prominent risk factor for several tumor types and is important in tumor evolution and progression. Here we...
8.
Mukherjee A, Kakati R, Van Alsten S, Laws T, Ebbs A, Hollern D, et al.
JCI Insight
. 2024 Oct;
9(23).
PMID: 39418101
Despite proven therapy options for estrogen receptor-positive (ER+) breast tumors, a substantial number of patients with ER+ breast cancer exhibit relapse with associated metastasis. Loss of expression of RasGAPs leads...
9.
Yang X, Hannig J, Hoadley K, Carmichael I, Marron J
J Comput Graph Stat
. 2024 Aug;
33(2):736-748.
PMID: 39170642
For measuring the strength of visually-observed subpopulation differences, the Population Difference Criterion is proposed to assess the statistical significance of visually observed subpopulation differences. It addresses the following challenges: in...
10.
Van Alsten S, Vohra S, Ivory J, Hamilton A, Gao X, Kirk E, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2400137.
PMID: 39013134
Purpose: Genomic tests, such as the Oncotype Dx 21-gene and Prosigna risk of recurrence (ROR-P) assay, are commonly used for breast cancer prognostication. Emerging data suggest variability between assays, but...